ESPS, Inc. Changes Name to Liquent, Inc.

Liquent to Continue to Help Life Sciences Customers Address Their Enterprise-

Wide Content Assembly and Electronic Publishing Challenges



Apr 30, 2001, 01:00 ET from Liquent, Inc.

    FORT WASHINGTON, Pa., April 30 /PRNewswire/ -- ESPS, Inc. (Nasdaq:   ESPS),
 the premier provider of electronic publishing solutions, today announced that
 it has changed its corporate name to Liquent, Inc.  The Company will maintain
 its current ticker symbol (ESPS) until NASDAQ approves a new symbol later this
 year.
     "The term `Liquent' captures and illustrates our fundamental belief that,
 in order to realize maximum value from its information assets, a business must
 be able to transform its content into a 'liquid' form that can flow, quickly
 and easily, from one format and use to another.  Liquent technology provides
 this 'liquid content,'" said Rick Dool, president and CEO of Liquent.  "We
 believe the Liquent name reflects the ongoing evolution of our technology, and
 represents our primary objective of providing the Life Sciences industry with
 more effective solutions to leverage content across the enterprise."
     Since 1994, the Company has developed software solutions - including
 CoreDossierX(R), kPortal(TM) and kPublisher(TM) -- that facilitate content
 reuse and repurposing by rendering documents from virtually any format and
 repository into PDF.  Earlier this year, the Company announced the formation
 of its Liquent division, which focused on pursuing OEM opportunities for
 Liquent Xtent(TM), a new rendering engine that transforms content into an XML
 format, which provides optimum flexibility for content reuse and repurposing.
     "As we look toward the future, we will continue to focus on developing new
 ways to enable our customers to convert their content so they can access,
 assemble, and repurpose it for any audience and any need.  Whether it is
 combining content to develop complex publications and dossiers, or distilling
 it down to the sentence and paragraph level -- our solutions are designed to
 do the job efficiently, reliably and cost-effectively.  This applies to both
 our flagship software, CoreDossierX, as well as our new technology, Xtent,"
 Dool added.
     "The new Liquent corporate name reflects the Company's intensified focus
 on serving its customers in the Life Sciences arena.  We are committed to
 developing solutions for our clients that leverage the latest technologies in
 regulatory publishing and beyond," said Norman Corn, executive vice president
 and general manager.  "At the same time, we will continue to provide a full
 continuum of services that address the needs of customers large and small, at
 every point in the product development lifecycle and throughout the
 enterprise."
 
     About Liquent
     Liquent, Inc., (formerly ESPS, Inc.) is the leading provider of content
 assembly and publishing solutions for the Life Sciences industry.  Built on
 proven, world-class rendering technology that transforms proprietary content
 into open formats such as XML and PDF, Liquent software and services are used
 by 18 of the top 20 global pharmaceutical companies.  As a result, Liquent's
 solutions - including its flagship software, CoreDossierX - have become the
 industry standards for the production of new drug applications (NDAs),
 reports, bids and proposals, and technical documentation.  Liquent's content
 middleware technology enables information assets to be assembled, published,
 and repurposed for maximum value.  Offering seamless integration with leading
 document management systems and file systems, Liquent's solutions retrieve
 information from virtually any source format and repository and automatically
 convert it into high-fidelity renditions that can be easily combined or
 distilled to meet any need.
     In addition to its headquarters in suburban Philadelphia, Liquent
 maintains offices in the United Kingdom; La Jolla, CA; Latham, NY; and
 Research Triangle Park, NC.
 
     CoreDossierX, Liquent, Liquent Xtent, kPublisher and kPortal  are
 trademarks or registered trademarks of ESPS, Inc. (d/b/a Liquent)
 
     The statements in this news release, which are not historical facts, are
 forward-looking statements.  These forward-looking statements involve risks
 and uncertainties that could render them materially different, including, but
 not limited to, the effect of fluctuations in the Company's operating results,
 the Company's reliance on a limited number of significant customers, the
 Company's reliance on its product family, the Company's ability to market and
 sell its products and services in its targeted industries, the Company's
 ability to expand its sales and professional services organizations, the
 Company's ability to manage growth, the Company's ability to attract and
 retain qualified personnel, the Company's reliance on relationships with
 service vendors, the Company's reliance on licensed technology, the Company's
 ability to protect its proprietary rights, the Company's ability to compete in
 the market, the development and growth of the market, the Company's ability to
 respond to changes in the market, and other risks detailed in its Securities
 and Exchange Commission filings, including the Registration Statement on Form
 S-1.
 
                               MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X66642072
 
 

SOURCE Liquent, Inc.
    FORT WASHINGTON, Pa., April 30 /PRNewswire/ -- ESPS, Inc. (Nasdaq:   ESPS),
 the premier provider of electronic publishing solutions, today announced that
 it has changed its corporate name to Liquent, Inc.  The Company will maintain
 its current ticker symbol (ESPS) until NASDAQ approves a new symbol later this
 year.
     "The term `Liquent' captures and illustrates our fundamental belief that,
 in order to realize maximum value from its information assets, a business must
 be able to transform its content into a 'liquid' form that can flow, quickly
 and easily, from one format and use to another.  Liquent technology provides
 this 'liquid content,'" said Rick Dool, president and CEO of Liquent.  "We
 believe the Liquent name reflects the ongoing evolution of our technology, and
 represents our primary objective of providing the Life Sciences industry with
 more effective solutions to leverage content across the enterprise."
     Since 1994, the Company has developed software solutions - including
 CoreDossierX(R), kPortal(TM) and kPublisher(TM) -- that facilitate content
 reuse and repurposing by rendering documents from virtually any format and
 repository into PDF.  Earlier this year, the Company announced the formation
 of its Liquent division, which focused on pursuing OEM opportunities for
 Liquent Xtent(TM), a new rendering engine that transforms content into an XML
 format, which provides optimum flexibility for content reuse and repurposing.
     "As we look toward the future, we will continue to focus on developing new
 ways to enable our customers to convert their content so they can access,
 assemble, and repurpose it for any audience and any need.  Whether it is
 combining content to develop complex publications and dossiers, or distilling
 it down to the sentence and paragraph level -- our solutions are designed to
 do the job efficiently, reliably and cost-effectively.  This applies to both
 our flagship software, CoreDossierX, as well as our new technology, Xtent,"
 Dool added.
     "The new Liquent corporate name reflects the Company's intensified focus
 on serving its customers in the Life Sciences arena.  We are committed to
 developing solutions for our clients that leverage the latest technologies in
 regulatory publishing and beyond," said Norman Corn, executive vice president
 and general manager.  "At the same time, we will continue to provide a full
 continuum of services that address the needs of customers large and small, at
 every point in the product development lifecycle and throughout the
 enterprise."
 
     About Liquent
     Liquent, Inc., (formerly ESPS, Inc.) is the leading provider of content
 assembly and publishing solutions for the Life Sciences industry.  Built on
 proven, world-class rendering technology that transforms proprietary content
 into open formats such as XML and PDF, Liquent software and services are used
 by 18 of the top 20 global pharmaceutical companies.  As a result, Liquent's
 solutions - including its flagship software, CoreDossierX - have become the
 industry standards for the production of new drug applications (NDAs),
 reports, bids and proposals, and technical documentation.  Liquent's content
 middleware technology enables information assets to be assembled, published,
 and repurposed for maximum value.  Offering seamless integration with leading
 document management systems and file systems, Liquent's solutions retrieve
 information from virtually any source format and repository and automatically
 convert it into high-fidelity renditions that can be easily combined or
 distilled to meet any need.
     In addition to its headquarters in suburban Philadelphia, Liquent
 maintains offices in the United Kingdom; La Jolla, CA; Latham, NY; and
 Research Triangle Park, NC.
 
     CoreDossierX, Liquent, Liquent Xtent, kPublisher and kPortal  are
 trademarks or registered trademarks of ESPS, Inc. (d/b/a Liquent)
 
     The statements in this news release, which are not historical facts, are
 forward-looking statements.  These forward-looking statements involve risks
 and uncertainties that could render them materially different, including, but
 not limited to, the effect of fluctuations in the Company's operating results,
 the Company's reliance on a limited number of significant customers, the
 Company's reliance on its product family, the Company's ability to market and
 sell its products and services in its targeted industries, the Company's
 ability to expand its sales and professional services organizations, the
 Company's ability to manage growth, the Company's ability to attract and
 retain qualified personnel, the Company's reliance on relationships with
 service vendors, the Company's reliance on licensed technology, the Company's
 ability to protect its proprietary rights, the Company's ability to compete in
 the market, the development and growth of the market, the Company's ability to
 respond to changes in the market, and other risks detailed in its Securities
 and Exchange Commission filings, including the Registration Statement on Form
 S-1.
 
                               MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X66642072
 
 SOURCE  Liquent, Inc.